Loading…
Loading…
VTYX (Ventyx Biosciences, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
VTYX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for VTYX and 80,000+ other tickers.
See exactly how VTYX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VTYX and 80,000+ other tickers.
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1)…
LOS ANGELES, April 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ventyx Biosciences, Inc., (“Ventyx" or the "Company") (NASDAQ: VTYX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F.
JPMorgan Chase and Co. lifted its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 748,088 shares of the company's stock after acquiring an additional 290,169 shares during the period. JPMorgan Chase
Ventyx Biosciences, Inc. (NASDAQ: VTYX - Get Free Report) shares saw unusually-high trading volume on Friday. Approximately 16,181,427 shares changed hands during mid-day trading, an increase of 257% from the previous session's volume of 4,538,231 shares.The stock last traded at $13.9850 and had previously closed at $13.97. Analysts Set New Price Targets A number of
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Analyst Recommendations This is a breakdown of recent
Cibc World Market Inc. reduced its position in Ventyx Biosciences, Inc. (NASDAQ: VTYX) by 39.1% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,250 shares of the company's stock after selling 99,750 shares during the period. Cibc World Market Inc.